Using Cell Signaling Activity, Rather Than Biomarkers, to Determine...

Using ACEA Bioscience instruments, scientists at the University of Minnesota demonstrated that a functional assay of patient derived tumor cells may be a key to personalized breast cancer therapy.(PRWeb December 19, 2016)Read the full story at http://www.prweb.com/releases/2016/12/prweb13932429.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: June 2019Source: Materials Science and Engineering: C, Volume 99Author(s): Milene Dalmina, Frederico Pittella, Jelver Alexander Sierra, Gabriela Regina Rosa Souza, Adny Henrique Silva, André Avelino Pasa, Tânia Beatriz Creczynski-PasaAbstractShort interfering RNA (siRNA) showed to be a viable alternative to a better prognosis in cancer therapy. Nevertheless, the successful application of this strategy still depends on the development of nanocarriers for the safe delivery of siRNA into the diseased tissue, which mostly occurs by passive accumulation. When an external magnetic field is applied,...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Bioconjugate ChemistryDOI: 10.1021/acs.bioconjchem.9b00028
Source: Bioconjugate Chemistry - Category: Biochemistry Authors: Source Type: research
In conclusion, the present study revealed that four vinca alkaloids and eribulin possessed potential Golgi-disrupting activity among a panel of 34 approved anticancer drugs. Other drugs covering various molecular-targeted drugs and classical DNA-damaging drugs showed no Golgi-disrupting effect. These results suggest that tubulin polymerization-inhibitors might be promising candidate drugs with Golgi-disrupting activity. PMID: 30787205 [PubMed - as supplied by publisher]
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Biol Pharm Bull Source Type: research
About one third of primary care providers discussed breast cancer treatment decisions with their patients, a new survey shows -- but it's not really their job.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ConclusionsThese findings demonstrate that aesthetic treatments for side-effects of cancer therapies can alleviate perceived distress and improve skin symptoms and HRQoL.
Source: Quality of Life Research - Category: Health Management Source Type: research
(Natural News) In case you still weren’t sure about whether or not cancer is one of the worst things that can ever happen to anyone, you only need to look at what happens with most female cancer patients after they have undergone treatment. In the case of breast cancer patients, it’s possible to suffer from...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
CONCLUSIONS: In the neoadjuvant setting, there is high- to low-certainty evidence of equivalent outcomes for the sequence in which taxanes are delivered. In the adjuvant setting, none of the studies reported on overall survival or disease-free survival. In most institutions, standard practice would be to deliver anthracycline followed by taxane, and currently available data do not support a change in this practice. We wait for the full-text publication of a relevant neoadjuvant study for women with HER2-negative breast cancer for inclusion in an update of this review. PMID: 30776132 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
In conclusion, our findings indicate that GPR120 acts as a cancer-promoting receptor in the development of breast cancer. Therefore, GPR120 is expected to be a potential new target for cancer therapy.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: PRECLINICAL REPORTS Source Type: research
n K. Iyer Targeting immune checkpoint molecules such as programmed death ligand-1 (PDL1) is an emerging strategy for anti-cancer therapy. However, transient expression of PDL1 and difficulty in tumor stroma penetration has limited the utility of anti-PDL1 therapy. To overcome these limitations, we report a new conjugate between the clinically approved PDL1 antibody (PDL1 AB) and drug Doxorubicin (Dox), named PDL1-Dox. We conjugated PDL1-Dox through a hydrazone linker containing a polyethylene glycol (PEG) spacer, which allows it to dissociate in a tumor environment and improves solubility. The purpose of using Dox is t...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 13 February 2019Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Sharad S. Singhal, Ravi Salgia, Sulabh Singhal, David Horne, Sanjay AwasthiAbstractBreast cancer (BC) is the most common cancer among women worldwide. Due to its complexity in nature, effective BC treatment can encounter many challenges. The human RALBP1 gene encodes a 76-kDa splice variant protein, RLIP (ral-binding protein1, RalBP1), a stress-protective mercapturic acid pathway (MAP) transporter protein, that also plays a key role in regulating clathrin-dependent endocytosis (CDE) as a Ral effector...
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Pharmaceuticals | University of Minnesota